The AMSP portal is an online marketplace that enables the supply of COVID-19-related critical diagnostics and medical equipment and consumables
ABIDJAN – bioMerieux, an international producer of vitro diagnostics for over 55 years and the Africa Medical Supplies Platform (AMSP), this week announced a new partnership to facilitate the supply of high-quality diagnostic solutions from the bioMérieux Pandemic Response Portfolio to African Union Member States.
The AMSP portal is an online marketplace that enables the supply of COVID-19-related critical diagnostics and medical equipment and consumables in Africa and the Caribbean Community (CARICOM). It was developed under the leadership of the African Union Special Envoy, Strive Masiyiwa and powered by Janngo, on behalf of the Africa Centres for Disease Control and Prevention (Africa CDC).
The platform was developed in partnership with African Export-Import Bank (Afreximbank) and the United Nations Economic Commission for Africa (ECA).
This partnership with bioMérieux aims to respond to supply shortages experienced by African Union Member States by guaranteeing efficient, uninterrupted and rapid access to bioMérieux high-quality diagnostic solutions dedicated to the COVID-19 pandemic.
Under the partnership, a portfolio of high-quality diagnostic solutions (molecular testing and serology testing) for COVID-19 from bioMérieux will be available at very competitive prices to each of the 55 African Union Member States.
“To effectively respond to the COVID-19 pandemic, Africa needs continuous and predictable supply of diagnostics and medical consumables, and the AMSP was created to close the supply gap. Through AMSP we are building partnerships and exploring all markets, and we are delighted to have bioMérieux join this very important partnership,” said Dr John Nkengasong, Director of Africa CDC.
A bioMerieux Africa official
also had positives to say about the partnership, which he said was a source of
pride to the company.
“We are very proud of this collaboration with AMSP, as it is part of our public health efforts which consist of allowing low and middle-income countries to have access to bioMérieux solutions in an ethical and equitable manner and to contribute to improve the health of patients and communities in these countries,” said Mr. Sindé Chekete, Vice-President, bioMérieux Africa.